Based on these results, abemaciclib has become the only CDK4/6 inhibitor approved as monotherapy for the treatment of patients with HR + /HER2- advanced BC whose disease progressed following prior endocrine therapy and chemotherapy. Here, CDK4 is linked to breast cancer.